PriceTargets.com logo

NASDAQ:GBIO - Generation Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.33
  • Forecasted Upside: 6.89 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$30.25 As of 01/22/2021 01:00 AM ET
▼ -0.36 (-1.18%)
1 month | 3 months | 12 months
Get New Generation Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBIO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$32.33
▲ +6.89% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Generation Bio in the last 3 months. The average price target is $32.33, with a high forecast of $38.00 and a low forecast of $28.00. The average price target represents a 6.89% upside from the last price of $30.25.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Generation Bio.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/3/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/7/2020JPMorgan Chase & Co.Initiated CoverageOverweight$28.00Medium
i
7/7/2020WedbushInitiated CoverageOutperform$31.00Medium
i
Rating by D. Nierengarten at Wedbush
7/7/2020CowenInitiated CoverageOutperformMedium
i
7/7/2020Jefferies Financial GroupInitiated CoverageBuy$38.00Medium
i
(Data available from 1/24/2016 forward)
Generation Bio logo
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $30.25
$29.20
$30.80

50 Day Range

MA: $33.23
$24.74
$48.85

52 Week Range

Now: $30.25
$17.00
$55.72

Volume

413,740 shs

Average Volume

1,402,553 shs

Market Capitalization

$1.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Generation Bio?

The following equities research analysts have issued reports on Generation Bio in the last twelve months: Cowen Inc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Wedbush, and Zacks Investment Research.

What is the current price target for Generation Bio?

3 Wall Street analysts have set twelve-month price targets for Generation Bio in the last year. Their average twelve-month price target is $32.33, suggesting a possible upside of 6.9%. Jefferies Financial Group Inc. has the highest price target set, predicting GBIO will reach $38.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $28.00 for Generation Bio in the next year.

What is the current consensus analyst rating for Generation Bio?

Generation Bio currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GBIO will outperform the market and that investors should add to their positions of Generation Bio.

What other companies compete with Generation Bio?

Other companies that are similar to Generation Bio include Schrödinger, TG Therapeutics, Turning Point Therapeutics, Evotec, Perrigo, Emergent BioSolutions, Blueprint Medicines, Amicus Therapeutics, Maravai LifeSciences, Eidos Therapeutics, Biohaven Pharmaceutical, Sage Therapeutics, Hutchison China MediTech, Arena Pharmaceuticals and Atea Pharmaceuticals.

How do I contact Generation Bio's investor relations team?

Generation Bio's physical mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company's listed phone number is 857-529-5908 and its investor relations email address is [email protected] The official website for Generation Bio is generationbio.com.